| 2022 | | A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer | 공태욱, 장석준 |
| 2018 | | A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2018 | | An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021) | 유희석 |
| 2015 | | Asian Society of Gynecologic Oncology International Workshop 2014. | 장석준 |
| 2019 | | Asian Society of Gynecologic Oncology International Workshop 2018 | 공태욱, 유희석, 장석준 |
| 2024 | | Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines | 손주혁, 장석준 |
| 2016 | | Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer | 백지흠 |
| 2011 | | Comparative proteomic analysis of advanced serous epithelial ovarian carcinoma: possible predictors of chemoresistant disease. | 백지흠 |
| 2024 | | Comparison of Outcomes in Bowel Resections by Gynecologic Oncologists Versus General Surgeons During Maximal Cytoreductive Surgery for Advanced Ovarian Cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3006) | 공태욱, 김지연, 손주혁, 장석준 |
| 2011 | | Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer. | 백지흠 |
| 2023 | | Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01) | 장석준 |
| 1996 | | CT and MR findings of Krukenberg tumors: comparison with primary ovarian tumors. | 박경주 |
| 1998 | | Diagnosis of ovarian torsion with color Doppler sonography: depiction of twisted vascular pedicle. | 권혁찬, 서정호, 이은주, 주희재 |
| 2011 | | Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice. | 백지흠 |
| 2006 | | Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. | 장기홍 |
| 2007 | | Dysgerminoma of the ovary with precocious puberty: a case report. | 유희석, 이정필, 장기홍, 한재호 |
| 2012 | | Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease | 장석준 |
| 2024 | | Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? | 장석준 |
| 2011 | | Feasibility and surgical outcomes of laparoscopic metastasectomy in the treatment of ovarian metastases from gastric cancer. | 백지흠 |
| 2017 | | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease | 장석준 |
| 2003 | | Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. | 장기홍 |
| 2023 | | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | 장석준 |
| 2023 | | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis | 손주혁, 장석준 |
| 2014 | | Isolated splenic metastasis of ovarian cancer detected with 18F-FDG PET/CT. | 안영실, 윤준기, 이수진 |
| 2024 | | Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study | 공태욱, 손주혁, 장석준 |
| 2023 | | Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3 | 공태욱 |
| 2024 | | Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer | 공태욱, 손주혁 |
| 2019 | | Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study | 김유찬 |
| 2024 | | MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs | 권지은 |
| 2004 | | Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. | 장기홍 |
| 2023 | | Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001) | 공태욱, 손주혁, 장석준 |
| 2015 | | Ovarian microcystic stromal tumor: A novel extracolonic tumor in familial adenomatous polyposis. | 고영화 |
| 2019 | | Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2017 | | Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer | 손주혁, 유희석, 장석준 |
| 2016 | | Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO) | 장석준 |
| 2018 | | Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement | 장석준 |
| 2017 | | Practice Patterns of Hereditary Ovarian Cancer Management in Korea | 장석준 |
| 2019 | | Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys | 장석준 |
| 2020 | | Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer | 이진구 |
| 2012 | | Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study | 김구상, 정용식 |
| 2024 | | Prognostic impact of erythropoietin-stimulating agent use during front-line chemotherapy in patients with ovarian cancer: A Korean multicenter cohort study | 김지연, 장석준 |
| 2011 | | Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. | 백지흠 |
| 2012 | | Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer | 유희석, 장석준 |
| 2018 | | Psychiatric comorbidities among ovarian cancer survivors in South Korea: A nationwide population-based, longitudinal study | 노오규, 오영택, 전미선, 허재성 |
| 2022 | | Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01) | 장석준 |
| 2006 | | Rare case of stage IA epithelial ovarian cancer with bone as the first site of recurrent metastasis. | 유희석, 이정필, 장기홍 |
| 2020 | | Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study | 장석준 |
| 2019 | | Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) | 장석준 |
| 2018 | | Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2023 | | Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004) | 공태욱, 김지연, 손주혁, 장석준 |
| 2016 | | Robotic single-site versus laparo-endoscopic single-site surgery for adnexal tumours: a propensity score-matching analysis | 공태욱, 백지흠, 유희석, 장석준 |
